Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
01 mai 2023 08h01 HE
|
Ocean Biomedical, Inc.
Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
27 avr. 2023 08h01 HE
|
Ocean Biomedical, Inc.
Results published in peer-reviewed Cancer Research share novel insights into Chi3L1’s role in modulating Glioma stem cells and reinforces the potential therapeutic impact of Anti-Chi3L1 Providence,...